2 completed, 2 unknown, 2 withdrawn. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Withdrawn 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Ohr Pharmaceutical Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab - Age-related Macular Degeneration | Phase 3 | Unknown | Ohr Pharmaceutical Inc. | 230 | 2016-04-12 | 2017-04-27 |
| Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab - Age-Related Macular Degeneration | Phase 2 | Withdrawn | Ohr Pharmaceutical Inc. | 2015-07-01 | 2017-04-27 | |
| Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME) Squalamine Lactate Ophthalmic Solution 0.2% - Diabetic Retinopathy | Phase 2 | Withdrawn | Starr Muscle | 2015-02-01 | 2016-06-01 | |
| Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion ranibizumab, Squalamine Lactate Ophthalmic Solution, 0.2% - Retinal Vein Occlusion, Macular Edema | Phase 1 / Phase 2 | Completed | Ohr Pharmaceutical Inc. | 20 | 2013-04-01 | 2015-11-25 |
| Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD) Squalamine lactate, Vehicle control - Neovascular Age Related Macular Degeneration | Phase 2 | Completed | Ohr Pharmaceutical Inc. | 142 | 2012-11-01 | 2015-06-12 |
| Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia OHR/AVR118 - Anorexia, Cancer Cachexia | Phase 2 | Unknown | Ohr Pharmaceutical Inc. | 20 | 2010-09-01 | 2012-11-27 |
Macular Degeneration (3) · Anorexia (1) · Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Fatigue (1) · Macular Edema (1) · Retinal Vein Occlusion (1) · Weight Loss (1)
Ranibizumab (3) · squalamine lactate (2) · EOM613 (1) · Exercise (1) · squalamine (1)
United States (4) · Canada (1)
Avner Ingerman, MD (2) · Daniel Roth, MD (1) · John Wroblewski, MD (1) · Martin Chasen, MBChB (1)